These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22236880)

  • 41. Retinoids Bias Integrin Expression and Function in Cutaneous T-Cell Lymphoma.
    Wang L; DeMarco SS; Chen J; Phillips CM; Bridges LC
    J Invest Dermatol; 2015 Aug; 135(8):2102-2108. PubMed ID: 25826424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas.
    Tensen CP; Vermeer MH; van der Stoop PM; van Beek P; Scheper RJ; Boorsma DM; Willemze R
    J Invest Dermatol; 1998 Aug; 111(2):222-6. PubMed ID: 9699721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting apoptosis defects in cutaneous T-cell lymphoma.
    Contassot E; French LE
    J Invest Dermatol; 2009 May; 129(5):1059-61. PubMed ID: 19369931
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma.
    Gluud M; Pallesen EMH; Buus TB; Gjerdrum LMR; Lindahl LM; Kamstrup MR; Bzorek M; Danielsen M; Bech R; Monteiro MN; Blümel E; Willerslev-Olsen A; Lykkebo-Valløe A; Vadivel CK; Krejsgaard T; Bonefeld CM; Geisler C; Becker JC; Koralov SB; Iversen L; Litman T; Woetmann A; Ødum N
    Blood; 2023 Jan; 141(2):180-193. PubMed ID: 36122387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma.
    Nagatani T; Miyazawa M; Matsuzaki T; Iemoto G; Kim ST; Baba N; Miyamoto H; Nakajima H
    Semin Dermatol; 1994 Sep; 13(3):216-22. PubMed ID: 7986691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.
    Clark RA; Shackelton JB; Watanabe R; Calarese A; Yamanaka K; Campbell JJ; Teague JE; Kuo HP; Hijnen D; Kupper TS
    Blood; 2011 Feb; 117(6):1966-76. PubMed ID: 21148332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function.
    Wolk K; Mitsui H; Witte K; Gellrich S; Gulati N; Humme D; Witte E; Gonsior M; Beyer M; Kadin ME; Volk HD; Krueger JG; Sterry W; Sabat R
    Clin Cancer Res; 2014 Nov; 20(21):5507-16. PubMed ID: 25212608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Large-cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor.
    Wolfe JT; Chooback L; Finn DT; Jaworsky C; Rook AH; Lessin SR
    J Clin Oncol; 1995 Jul; 13(7):1751-7. PubMed ID: 7602365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.
    Krejsgaard T; Litvinov IV; Wang Y; Xia L; Willerslev-Olsen A; Koralov SB; Kopp KL; Bonefeld CM; Wasik MA; Geisler C; Woetmann A; Zhou Y; Sasseville D; Odum N
    Blood; 2013 Aug; 122(6):943-50. PubMed ID: 23801634
    [TBL] [Abstract][Full Text] [Related]  

  • 50. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.
    Verma NK; Davies AM; Long A; Kelleher D; Volkov Y
    Cell Mol Biol Lett; 2010 Jun; 15(2):342-55. PubMed ID: 20213502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.
    Lauenborg B; Christensen L; Ralfkiaer U; Kopp KL; Jønson L; Dabelsteen S; Bonefeld CM; Geisler C; Gjerdrum LM; Zhang Q; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Oncotarget; 2015 Jun; 6(17):15235-49. PubMed ID: 25915535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. Clinical, histopathologic, and immunohistochemical analyses.
    Nagatani T; Matsuzaki T; Iemoto G; Kim S; Baba N; Miyamoto H; Nakajima H
    Cancer; 1990 Dec; 66(11):2380-6. PubMed ID: 2245393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.
    Litvinov IV; Cordeiro B; Huang Y; Zargham H; Pehr K; Doré MA; Gilbert M; Zhou Y; Kupper TS; Sasseville D
    Clin Cancer Res; 2014 Jul; 20(14):3799-808. PubMed ID: 24850846
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pathogenesis of large cell transformation in cutaneous T-cell lymphoma is not associated with t(2;5)(p23;q35) chromosomal translocation.
    Li G; Salhany KE; Rook AH; Lessin SR
    J Cutan Pathol; 1997 Aug; 24(7):403-8. PubMed ID: 9274957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
    Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover.
    Krejsgaard T; Lindahl LM; Mongan NP; Wasik MA; Litvinov IV; Iversen L; Langhoff E; Woetmann A; Odum N
    Semin Immunopathol; 2017 Apr; 39(3):269-282. PubMed ID: 27717961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.
    Kopp KL; Ralfkiaer U; Gjerdrum LM; Helvad R; Pedersen IH; Litman T; Jønson L; Hagedorn PH; Krejsgaard T; Gniadecki R; Bonefeld CM; Skov L; Geisler C; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Cell Cycle; 2013 Jun; 12(12):1939-47. PubMed ID: 23676217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
    Huang Y; Su MW; Jiang X; Zhou Y
    Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells.
    Zhang CL; Kamarashev J; Qin JZ; Burg G; Dummer R; Döbbeling U
    J Pathol; 2003 Jun; 200(2):249-54. PubMed ID: 12754746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.